# Christoph Huber

> Christoph Huber is a startup investor at BioNTech (Mainz). See 0 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [BioNTech](https://shizune.co/investors/profile/biontech-ag)
- Location: Mainz, Germany
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/christoph-huber-195b2317

Christoph Huber is a startup investor at BioNTech in Mainz. After his studies at Medical School of the Leopold Franzens University in Innsbruck,Christoph Huber gained experience as a health professional of internal medicine and received his Ph.D. Several research scientist visits (Dept. Tumor Biology of Karolinska Institute, Stockholm, Wallenberg Laboratorium, Dept. Immunology of Uppsala University) werefollowed by an education in clinical bone marrow transplantation at the Fred Hutchinson Cancer Research Center, Seattle. Back in Innsbruck, Huber headed the bone marrow transplantation section of the Department of Internal Medicine, eventually becoming Professor of Clinical Immunobiology. Huber is Emeritus Professor of Medicine at the Medical School of the Johannes Gutenberg University in Mainz, co-founder and board member of the Translational Oncology research organization and co-founder and Head of Supervisory Board at the Cluster for individualized immune intervention (CI-3). Huber also co-founded the biopharmaceutical companies Ganymed Pharmaceuticals and BioNTech and serves on both of their boards. Huber is a member of numerous scientific committees, in particular the international Association of Cancer Immunotherapy (CIMT), which he co-founded and chairs. Huber is the author of more than 250 publications, among them various articles in “Nature”, “Nature Immunology”, “Immunity”, and the “Journal of Experimental Medicine”.

## About BioNTech

VC Fund · Mainz, Germany

BioNTech is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. It contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates.

5 contacts available at BioNTech.

| Name | Title | Profile |
| --- | --- | --- |
| Annemarie Hanekamp | Chief Commercial Officer | https://shizune.co/investors/profile/annemarie-hanekamp-7efc |
| Arvind m. Hundal Ph.d. | SVP Business Development | https://shizune.co/investors/profile/arvind-m-hundal |
| Christoph Huber | Cofounder & deputy chair supervisory board | https://shizune.co/investors/profile/christoph-huber |
| Christoph Kröner | Director DNA Process Development & Cap Technology | https://shizune.co/investors/profile/christoph-kr%C3%B6ner |
| Jesse Dong | Vice President, Peptide Chemistry | https://shizune.co/investors/profile/jesse-dong |

## FAQ

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co